{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04493385",
            "orgStudyIdInfo": {
                "id": "019-297"
            },
            "organization": {
                "fullName": "Baylor Research Institute",
                "class": "OTHER"
            },
            "briefTitle": "The Hepatitis C Transplant Collaborative",
            "officialTitle": "Nationwide Hepatitis C NAT+ Cardiac Transplant Experience",
            "therapeuticArea": [
                "Cardiovascular",
                "Gastroenterology"
            ],
            "study": "the-hepatitis-c-transplant-collaborative"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-01",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-09-16",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-07-13",
            "studyFirstSubmitQcDate": "2020-07-29",
            "studyFirstPostDateStruct": {
                "date": "2020-07-30",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-01-25",
            "lastUpdatePostDateStruct": {
                "date": "2023-01-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Baylor Research Institute",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "In this study we seek to test the hypothesis that safety and clinical outcomes after cardiac transplantation utilizing HCV NAT+ donor organs as currently performed are acceptable.",
            "detailedDescription": "Organ offers from donors with prior or chronic hepatitis C virus (HCV) exposure have been historically underutilized for orthotopic heart transplantation because of the post-transplantation risks \\[1, 2\\]. The use of HCV antibody-positive (Ab+) donors was associated with attenuated survival benefit after heart transplant and increased coronary allograft vasculopathy in the era before new highly effective direct-acting antiviral agents (DAAs) were developed \\[3-5\\]. These DAAs target multiple steps in the HCV replication life cycle \\[6\\]. Newer, well-tolerated, oral direct-acting antivirals (DAAs) have recently been transforming thoracic transplant outcomes after donor-derived HCV transmission. Moreover, now that HCV nucleic-acid testing (NAT), a polymerase chain reaction (PCR)-based approach to detecting viral activity, is widely available and used on all US donor organs, transplant centers have more relevant information about the donor, allowing better risk assessments.\n\nAs a result, the utilization of HCV NAT+ donor hearts for transplantation is rapidly gaining momentum, with the obvious benefits of an enlarged donor pool \\[7\\]. Appropriately, clinical safety trials are currently underway, including a multicenter effort led by the PI of this proposal. Moreover, since the last \\~2 years many transplant centers across the nation have started transplanting HCV NAT+ donor organs as standard of care. We estimate that the number of HCV+ cardiac transplants is quickly outpacing the number of trial participants. Hence, it is imperative that safety assessments and risk analyses 'catch up with the real world'."
        },
        "conditionsModule": {
            "conditions": [
                "Transplant; Failure, Heart",
                "Hepatitis C"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "RETROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of donor HCV nucleic-acid testing positive (HCV NAT+) cardiac transplantation",
                    "description": "To assess the current status of donor HCV NAT+ cardiac transplantation via retrospective data collection.",
                    "timeFrame": "6.5 years"
                },
                {
                    "measure": "Failure versus Cure Rate for HCV NAT+ Heart Transplants",
                    "description": "sustained viral response (SVR)-12 (cure-rate) for HCV negative recipient",
                    "timeFrame": "6.5 years"
                },
                {
                    "measure": "Rate of Primary graft dysfunction (PGD)",
                    "description": "Rate of Expected Post-Transplant Risks",
                    "timeFrame": "30 days"
                },
                {
                    "measure": "1 year mortality",
                    "description": "Number of deaths",
                    "timeFrame": "1 Year"
                },
                {
                    "measure": "Cellular graft rejection rate",
                    "description": "Graft rejection rate",
                    "timeFrame": "6.5 years"
                },
                {
                    "measure": "Antibody Mediated Rejection rate",
                    "description": "Graft rejection rate",
                    "timeFrame": "6.5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Recipient of a proven HCV NAT+ donor heart.\n2. Re-transplant patients will be included.\n\nExclusion Criteria:\n\n1. Multi-organ transplantation",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Cardiac transplant recipients utilizing HCV NAT+ donor organs",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Joost Felius, PhD",
                    "role": "CONTACT",
                    "phone": "214-818-8943",
                    "email": "Joost.Felius@BSWHEALTH.ORG"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Shelley A Hall, MD FACC",
                    "affiliation": "BSWRI",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Baylor Scott & White Health Research Institute",
                    "status": "RECRUITING",
                    "city": "Dallas",
                    "state": "Texas",
                    "zip": "75246",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Joost Felius, PhD",
                            "role": "CONTACT",
                            "phone": "214-818-8943",
                            "email": "Joost.Felius@BSWHEALTH.ORG"
                        }
                    ],
                    "geoPoint": {
                        "lat": 32.78306,
                        "lon": -96.80667
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "21912770",
                    "type": "BACKGROUND",
                    "citation": "Kim EY, Ko HH, Yoshida EM. A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol. 2011 Aug;25(8):445-8. doi: 10.1155/2011/947838."
                },
                {
                    "pmid": "26615769",
                    "type": "BACKGROUND",
                    "citation": "Englum BR, Ganapathi AM, Speicher PJ, Gulack BC, Snyder LD, Davis RD, Hartwig MG. Impact of donor and recipient hepatitis C status in lung transplantation. J Heart Lung Transplant. 2016 Feb;35(2):228-35. doi: 10.1016/j.healun.2015.10.012. Epub 2015 Oct 9."
                },
                {
                    "pmid": "17047214",
                    "type": "BACKGROUND",
                    "citation": "Gasink LB, Blumberg EA, Localio AR, Desai SS, Israni AK, Lautenbach E. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients. JAMA. 2006 Oct 18;296(15):1843-50. doi: 10.1001/jama.296.15.1843."
                },
                {
                    "pmid": "15019636",
                    "type": "BACKGROUND",
                    "citation": "Haji SA, Starling RC, Avery RK, Mawhorter S, Tuzcu EM, Schoenhagen P, Cook DJ, Ratliff NB, McCarthy PM, Young JB, Yamani MH. Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation. J Heart Lung Transplant. 2004 Mar;23(3):277-83. doi: 10.1016/S1053-2498(03)00148-7."
                },
                {
                    "pmid": "27928718",
                    "type": "BACKGROUND",
                    "citation": "Lee R, Kottilil S, Wilson E. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Hepatol Int. 2017 Mar;11(2):161-170. doi: 10.1007/s12072-016-9776-8. Epub 2016 Dec 7."
                },
                {
                    "pmid": "26725897",
                    "type": "BACKGROUND",
                    "citation": "Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int. 2016 Jan;36 Suppl 1:47-57. doi: 10.1111/liv.13027."
                },
                {
                    "pmid": "29774177",
                    "type": "BACKGROUND",
                    "citation": "Gottlieb RL, Hall SA. The New Direct Antiviral Agents and Hepatitis C in Thoracic Transplantation: Impact on Donors and Recipients. Curr Transplant Rep. 2018;5(2):145-152. doi: 10.1007/s40472-018-0192-y. Epub 2018 Apr 10."
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006506",
                    "term": "Hepatitis A"
                },
                {
                    "id": "D000006526",
                    "term": "Hepatitis C"
                },
                {
                    "id": "D000006505",
                    "term": "Hepatitis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000008107",
                    "term": "Liver Diseases"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000006525",
                    "term": "Hepatitis, Viral, Human"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000004769",
                    "term": "Enterovirus Infections"
                },
                {
                    "id": "D000010850",
                    "term": "Picornaviridae Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000086982",
                    "term": "Blood-Borne Infections"
                },
                {
                    "id": "D000003141",
                    "term": "Communicable Diseases"
                },
                {
                    "id": "D000018178",
                    "term": "Flaviviridae Infections"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9592",
                    "name": "Hepatitis A",
                    "asFound": "Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9591",
                    "name": "Hepatitis",
                    "asFound": "Hepatitis",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9611",
                    "name": "Hepatitis C",
                    "asFound": "Hepatitis C",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11107",
                    "name": "Liver Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9610",
                    "name": "Hepatitis, Viral, Human",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M7930",
                    "name": "Enterovirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M13745",
                    "name": "Picornaviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M2593",
                    "name": "Blood-Borne Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M20324",
                    "name": "Flaviviridae Infections",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}